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The Department of Health recommends annual vaccination for
patients at high risk of morbidity and mortality from influenza
(Department of Health, 1996). Patients with lung cancer fall into
this category because of chronic respiratory disease and immuno-
suppression due to cancer or treatment. There are increasing data
on the impact of influenza in adults with cancer (Yousuf et al,
1997), but knowledge of serological responses to inactivated flu
vaccine in adults with cancer, particularly those treated with
steroids, remains scanty.
PATIENTS AND METHODS
Between October and November 1996, patients with lung cancer
attending the Northwest regional oncology outpatient clinic were
asked to participate in a study to assess serological responses to
inactivated influenza vaccine. Local ethics approval was obtained
and patients gave written informed consent. Individuals were
excluded from the study if they had already received vaccine from
their GP or were allergic to eggs. Fluvirin (Evans Medical Ltd)
containing inactivated A/Singapore/6/86 (H1N1), A/Wuhan/
359/95 (H3N2) and B/Beijing/184/93 was administered as a single
subcutaneous injection. A 10 ml serum sample was taken prior to
vaccination and a second sample 4–6 weeks later. Prevaccination
susceptibility and post-vaccination serological responses to the
three influenza antigens were determined by haemagglutination
inhibition (HI). A reciprocal HI titre of ³ 40 was considered
protective. All patients were given a viral swab kit and instructions
on collecting nose and throat swabs if they developed symptoms
suggestive of influenza.
RESULTS
Sixty-seven patients were recruited, of which 59 (36 male) had
paired sera available for analysis. The median age was 62 years
(range 45–75). Twenty one had small cell (14 extensive stage) and
38 non-small cell lung cancer (35 TNM stage III–IV disease).
Twenty patients received influenza vaccine in the previous year.
Fourteen patients had received chemotherapy in the preceding 4
weeks and 22 patients were receiving oral corticosteroids.
Prevaccination HI serology showed that 18/59 patients (31%)
were immune to all three influenza strains. Twelve of these (67%)
were individuals who had received influenza vaccine the previous
year. 21/59 patients (36%) were susceptible to all three virus
strains, and the remaining 34% (20/59) were susceptible to either
one or two strains of influenza. 62% (13/21) of fully-susceptible
individuals made a complete protective response to influenza
vaccine and a further seven (33%) made a protective response to
one or two antigens (Table 1). Only one fully-susceptible patient
failed to make any protective responses. Overall, 83% of all
patients were fully immune to influenza following vaccination.
During the course of the study, five patients submitted combined
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Table 1 Pre- and post-vaccination influenza virus susceptibility
Post-vaccination protection* (n (%))
Prevaccination n
status Full Partial None
Immune to all 3 strains 18 17 (94%) 1 (6%) 0
Susceptible to
3 strains 21 13 (62%) 7 (33%) 1 (5%)
2 strains 11 10 (91%) 1 (9%) 0
1 strain 9 9 (100%) 0 0
Total 41 32 (78%) 8 (20%) 1 (2%)
Grand Total 49 (83%)
*Full protection is defined as HI titre ³ 40 to all three influenza antigens;
partial protection is defined as HI titre ³ 40 to one or two influenza antigens.nose and throat swabs for virus culture, from which no viruses
were recovered.
Analysis of factors which may have influenced vaccine
response in those susceptible (Table 2), using a comparison of
independent proportions (c2 test), showed that lung cancer
histology, chemotherapy in the previous 4 weeks or systemic
steroid medication had no effect on seroconversion, or the
attainment of a protective HI response in susceptible lung cancer
patients. A within-subject linear model was used to estimate the
increase in HI titre post-vaccination; this was 13-fold for H1N1,
7-fold for H3N2, and 6-fold for influenza B. There was weak
evidence that the increase in HI titre post-vaccination was larger as
patient white cell counts increased for both A strains (P = 0.06 for
H1N1, P = 0.08 for H3N2), but not for the B strain.
DISCUSSION
The serological responses obtained from this group of lung cancer
patients indicates that 32/41 (78%) of lung cancer patients suscep-
tible to one or more influenza strains responded fully to vaccina-
tion with inactivated influenza vaccine. This level of response is
comparable to responses obtained from normal healthy volunteers
(Department of Health, 1996; Lorio et al, 1989).
There are several studies of influenza vaccination in malig-
nancy. Shildt et al (1979) found that lymphoma patients had the
lowest antibody responses. He looked at 82 patients with different
malignancies, only 14 had lung cancer. Ortbals et al (1977) studied
42 patients who received whole virus vaccine of whom 21 had
solid tumours and one had lung cancer. The most interesting result
of this study was data showing a 50% response rate if patients
were vaccinated at the time of chemotherapy but a 93% response
rate if they were vaccinated between courses of chemotherapy. In
our study, all patients on chemotherapy were vaccinated between
courses of treatment.
Research into new therapies for lung cancer includes tumour
vaccine therapy. The ability of lung cancer patients to develop a
protective response to influenza vaccine despite chemotherapy and
systemic corticosteroids suggests that this approach may be useful.
In this small study, protective responses to influenza vaccine did
not appear to be affected by systemic steroid treatment, recent
chemotherapy or lung cancer histology.
Less than 50% of high-risk patients receive influenza vaccine
for a variety of reasons (Editorial, 1997). Advice from treating
physicians to general practitioners that influenza vaccine is effec-
tive in lung cancer patients may increase its use (Watkins, 1997).
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Table 2 Post-vaccination influenza virus protection analysed according to patient variables
Subgroup (n) Immune  Post-vaccination protection (n (%))
prevaccination
(n (%)) Full Partial None
Small cell histology (38) 11 (29%) 32 (84%) 5 (13%) 1 (3%)
Non-small cell histology (21) 7 (33%) 17 (81%) 4 (19%) 0
Recent chemotherapy (14) 3 (21%) 11 (79%) 3 (21%) 0
No chemotherapy (45) 15 (33%) 38 (84%) 6 (13%) 1 (2%)
On steroids (22) 7 (32%) 19 (86%) 3 (14%) 0
No steroids (37) 11 (30%) 30 (81%) 6 (16%) 1
P values for small cell vs non-small cell histology, chemotherapy vs no recent chemotherapy and systemic
corticosteroids vs none were all > 0.6 (Fishers exact test).